If you purchased shares of Cell Therapeutics, Inc. (NASDAQ:CTIC)
The new investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Cell Therapeutics, Inc. (NASDAQ:CTIC)
On January 30, 2012, Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced that it has withdrawn its New Drug Application ("NDA") for Pixuvri (pixantrone)
Cell Therapeutics, Inc said the NDA was withdrawn because, after communications with the FDA, Cell Therapeutics, Inc needed additional time to prepare for the review of the Pixuvri NDA by the FDA's Oncologic Drugs Advisory Committee at its February 9, 2012 meeting. Prior to withdrawing the NDA, Cell Therapeutics, Inc requested that the FDA consider rescheduling the review of the Pixuvri NDA to the Oncologic Drugs Advisory Committee meeting to be held in late March. The FDA was unable to accommodate Cell Therapeutics’
As a result of the withdrawal of the NDA, the FDA will no longer make a decision.
Cell Therapeutics already faces a lawsuit a filed by investors who invested in the time frame between March 25, 2008 and March 22, 2010. The plaintiff in that complaint alleges that defendants, among other things, failed to disclose that the Special Protocol Assessment (“SPA”) with theFDA for pixantrone was invalidated in March 2008;
Shares of Cell Therapeutics, Inc. (Public, NASDAQ:CTIC)
Those who purchased shares of Cell Therapeutics, Inc. (NASDAQ:CTIC)
# # #
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.